Navigation Links
GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
Date:3/10/2008

rvical cancer candidate vaccine in March 2007.

About GlaxoSmithKline

GlaxoSmithKline--one of the world's leading research-based pharmaceutical and healthcare companies--is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, please visit http://www.gsk.com/media.

GSK Biologicals (GSK Bio), one of the world's leading vaccine manufacturers, is headquartered in Rixensart, Belgium, where the majority of GlaxoSmithKline's activities in the field of vaccine research, development and production are conducted. GSK Bio employs more than 1,500 scientists, who are devoted to discovering new vaccines and developing more cost-effective and convenient combination products to prevent infections that cause serious medical problems worldwide. In 2006, GSK Bio distributed more than 1.1 billion doses of vaccines to 169 countries in both the developed and the developing world -- an average of 3 million doses a day. Of those vaccine doses, approximately 136 million were doses of combination pediatric vaccines which protect the world's children with up to six diseases in one vaccine.

Inquiries:

US Media Inquiries: Liad Diamond (919) 483 2839

European Analyst/Investor Inquiries: David Mawdsley +44 20 8047 5564

Sally Ferguson +44 20 8047 5543

US Analyst/Investor Inquiries: Frank Murdolo (215) 751 7002

Tom Curry (215) 751 5419

References:

(1) Harper D, Gall S, et al. HPV-007 Efficacy Abstract. "Sustained

Immunogenicity and high efficacy against HPV-16/18 related cervical

neoplasia: Long-term follow-up through 6.4 years in women vaccinated

with CERVARIX (GSKS HPV 16/18 AS04 Candidate vaccine)" To be

present
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
3. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
6. Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients
7. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
8. Thomson Healthcare Cancer Profiler Used in Study
9. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
10. CMC, Moffitt Partner to Study Cancer
11. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... According to Marcia Crosse (Director, Health Care at GAO ... health has been compromised. In her comments on why oversight ... says : "The Food and Drug ... all Americans. FDA,s role is far-reaching: from over-the-counter pain relievers ...
... 19, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... leading China-based pharmaceutical and biotechnology research and development ... the first milestone in its strategic partnership with ... Chinese pharmaceutical company, to develop novel therapeutic monoclonal ...
Cached Medicine Technology:Physician-Patient Alliance for Health & Safety: Can There Be Too Much FDA Oversight? 2Physician-Patient Alliance for Health & Safety: Can There Be Too Much FDA Oversight? 3Physician-Patient Alliance for Health & Safety: Can There Be Too Much FDA Oversight? 4ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui 2ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui 3ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui 4
(Date:4/17/2014)... Queen,s University Belfast,s Vice-Chancellor, Professor Patrick Johnston, whose work ... elected as a Fellow of the European Academy of ... is an independent advisory body of highly distinguished oncologists ... and suffering caused by cancer in Europe. , Professor ... Northern Ireland move from the bottom of the UK ...
(Date:4/16/2014)... STANFORD, Calif. Consider the marvel of the embryo. It ... and function as they multiply to become the cells of ... of the body. , Now, in a feat of reverse ... complex genetic coding that allows embryonic cells to proliferate and ...
(Date:4/16/2014)... A team that includes scientists from the School of ... San Antonio, Johns Hopkins University and St. Mary,s University reported ... to infect the body. , The fungal pathogen Candida ... and is the most common fungal pathogen to infect humans. ...
(Date:4/15/2014)... the United States have nearly doubled since 1988, suggests new ... with obesity apparently to blame for the surge. The researchers ... hit all groups equally, with alarming increases in diabetes in ... reported in the April 15, 2014 issue of the ...
(Date:4/15/2014)... the RECIST Working Group published in the European Journal ... refined categorization of tumor response or various aspects of progression ... They found that modeling target lesion tumor growth did ... that of the other components of progression. The RECIST Working ...
Breaking Medicine News(10 mins):Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Can refined categorization improve prediction of patient survival in RECIST 1.1? 2
... By Randy Dotinga HealthDay Reporter , WEDNESDAY, ... certain heart patients will fare about the same whether ... that uses drug-coated stents to prop open clogged arteries. ... procedures, which also require much less recovery time. However, ...
... Cincinnati (UC) and Cincinnati Children,s Hospital Medical Center ... primarily to prevent rejection in organ transplant patients, ... The Multicenter International LAM Efficacy of Sirolimus ... designed to develop a therapy for this life-threatening ...
... MD, MPH, Medical Director and Principal Investigator of IMPACT ... Children,s National Medical Center, served as the Site Principal Investigator ... outcomes, specifically for inner-city children and teens. Findings from a ... were published and released in the March 17 issue of ...
... By Steven Reinberg HealthDay Reporter , ... in the United States reached an all-time low in ... percent from 2008, federal health officials report. , "There ... a statistician at the U.S. Centers for Disease Control ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... drug cytarabine work as well as the high doses that ... fewer side effects, a new Dutch study finds. Cytarabine ... along with other chemotherapy drugs and stem cell transplantation. Cytarabine ...
... It is no surprise to scientists that the largest social ... their face is fundamental to our social interactions, one of ... how our brain processes facial identity. In a ... scientists used an original approach a method that "shakes" ...
Cached Medicine News:Health News:Bypass Surgery, Stents Seem to Bring Same Level of Relief 2Health News:Bypass Surgery, Stents Seem to Bring Same Level of Relief 3Health News:New therapy found for rare lung disorder 2Health News:New therapy found for rare lung disorder 3Health News:Stephen J. Teach, MD, MPH, part of landmark study on pediatric asthma 2Health News:U.S. Death Rate at All-Time Low: CDC 2Health News:U.S. Death Rate at All-Time Low: CDC 3Health News:Less Is More With Acute Myeloid Leukemia Drug 2Health News:Innovative technique gives vision researchers insight into how people recognize faces 2
... Control of thumb motion can be ... stroke, for persons with spinal cord injuries ... due to cerebral palsy or other motor ... positions the thumb for control and coordination. ...
... stabilizes the MP joint and the CMC joint of ... of both of the thumb joints. An excellent choice ... but who need maximum mobility for daily activities. Ideal ... thumb and for those with pain due to repetitive ...
... profile contour at the palmar crease to allow ... excellent choice to treat mild to moderate wrist ... wear following cast removal. The lightweight laminated ... fasteners provides support and compression to the wrist ...
... common site for arthritis in the hand. The ... the wrist or other joints of the thumb. ... or reduce subluxation of the CMC joint of ... without pain. Also useful for persons experiencing pain ...
Medicine Products: